|Table of Contents|

Research progress of c-Met in lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 01
Page:
174-178
Research Field:
Publishing date:

Info

Title:
Research progress of c-Met in lung cancer
Author(s):
ZHAO Bochen; LU Dan
Department of Oncology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China.
Keywords:
lung cancer; c-Met; targeted therapy
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.01.039
Abstract:
C-Met is a kind of tyrosine kinase receptor,which is encoded by MET gene.Hepatocyte growth factor(HGF),as the only natural ligand of c-Met,activates related downstream pathways such as PI3K,MAPK and STAT 3 after binding to it,which is involved in tumor proliferation,migration,invasion and so on.The main activation forms of c-Met include ligand-dependent autocrine or paracrine mechanism and non-ligand-dependent mechanism.Many malignant tumors,including lung cancer,have a variety of abnormal activation mechanisms of c-Met.It has been found that the abnormal activation of c-Met is also involved in the occurrence,development and prognosis of lung cancer.Because the role of c-Met signaling pathway in the progress and invasion of lung cancer has been widely studied,c-Met related inhibitors show antitumor activity in both preclinical and clinical trials of lung cancer.Therefore,this paper briefly reviews the relationship between the structure and function of c-Met and its abnormal activation mechanism and the occurrence and development of lung cancer,as well as the research progress of targeted drugs related to this pathway in the treatment of lung cancer.

References:

[1] GIULIA PASQUINI,GIUSEPPE GIACCONE.C-MET inhibitors for advanced non-small cell lung cancer［J］.Expert Opinion on Investigational Drugs,2018,27(4):363-375.
[2]周韶璋.HGF/c-Met信号传导通路与晚期非小细胞肺癌关系的研究进展［J］.中国癌症防治杂志,2015,7(5):375-379. ZHOU SZ.Advances in the relationship between HGF/c-Met signaling pathway and advanced non-small cell lung cancer［J］.Chinese Journal of Cancer Prevention,2015,7(5):375-379.
[3]HUGHES VERONICA S,SIEMANN DIETMAR W.Failures in preclinical and clinical trials of c-Met inhibitors:evaluation of pathway activity as a promising selection criterion［J］.Oncotarget,2019,10(2):184-197.
[4]宁瑞玲,于起涛,周韶璋,等.c-MET与肺癌EGFR-TKIs耐药关系研究进展［J］.内科,2018,13(2):202-203. NING RL,YU QT,ZHOU SZ,et al.Advances in research on relationship between c-MET and EGFR-TKIs resistance in lung cancer［J］.Internal Medicine,2018,13(2):202-203.
[5]黄美欧.MACC1和c-Met蛋白在肺腺癌组织中的表达变化及其术后复发预测应用分析［J］.现代诊断与治疗,2017,28(14):2712-2713. HONG MO.Expression changes of MACC1 and c-Met proteins in lung adenocarcinoma and their application in predicting postoperative recurrence［J］.Modern Diagnosis and Treatment,2017,28(14):2712-2713.
[6]徐建平,赵洁婷,叶伟,等.HGF、c-MET及VEGF在非小细胞肺癌中的表达和意义［J］.实用癌症杂志，2017,32(4):528-530. XU JP,ZHAO JT,YE W,et al.Expression and significance of HGF,c-MET and VEGF in non-small cell lung cancer［J］.Practical Cancer Journal,2017,32(4):528-530.
[7] GEORGIOS TSAKONAS,JOHAN BOTLING,PATRICK MICKE,et al.c-MET as a biomarker in patients with surgically resected non-small cell lung cancer［J］.Lung Cancer,2019,133:69-74.
[8] ALEXANDER DRILON,FEDERICO CAPPUZZO,SAI-HONG IGNATIUS OU,et al.Targeting MET inlung cancer:will expectations finally be MET［J］.Journal of Thoracic Oncology,2017,12(1):15-26.
[9] KUMAR A,KUMAR V,SINGH K,et al.Therapeutic advances for huntington's disease［J］.Brain Sci,2021,10(1):43-45.
[10]SALGIA R,SATTLER M,SCHEELE J,STROH C,et al.The promise of selective met inhibitors in non-small cell lung cancer with met exon 14 skipping［J］.Cancer Treatment Reviews,2021,87:102022-102023.
[11]尹利梅,卢铀.MET14外显子跳跃突变在非小细胞肺癌中的研究进展［J］.中国肺癌杂志,2018,21(7):553-559. YIN LM,LU Y.Progress in MET14 exon skipping mutation in non-small cell lung cancer［J］.Chinese Journal of Lung Cancer,2018,21(7):553-559.
[12]GOW CHIEN HUNG,HSIEH MIN SHU,WU SHANG GIN,et al.A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population［J］.Lung Cancer,2017,103:82-89.
[13]TONG JOANNA H,YEUNG SAI F,CHAN ANTHONY WH,et al.MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis［J］.Clinical Cancer Research,2016,22(12):3048-3056.
[14]CORTOT ALEXIS B,KHERROUCHE ZOULIKA,DESCARPENTRIES CLOTILDE,et al.Exon 14 deleted MET receptor as a new biomarker and target in cancers［J］.Journal of the National Cancer Institute,2017,109(5):101-102.
[15]FICHTENHOLTZ ALEX,OU SAI-HONG IGNATIUS,JENTZ DAVID,et al.Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors［J］.Cancer Discovery,2015,5(8):850-859.
[16] AWAD MARK M,OXNARD GEOFFREY R,JACKMAN DAVID M,et al.MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression［J］.Journal of Clinical Oncology,2016,34(7):721-730.
[17]KIM EK,KIM KA,LEE CY,et al.Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer［J］.Clin Lung Cancer,2019,20:123-132.
[18] VUONG HG,HO ATN,ALTIBI AM,et al.Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer-a systematic review and meta-analysis［J］.Lung Cancer,2018,123:76-82.
[19] PLENKER D,BERTRAND M,DE LANGEN AJ,et al.Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients［J］.Clin Cancer Res,2018,24(6):1337-1343.
[20]DAVIES KD,NG TL,ESTRADA-BERNAL A,et al.Dramatic response to crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion［J］.JCOTM Precision Oncology,2017,2017(1):1-6.
[21]CHO JH,KU BM,SUN JM,et al.KIF5B-MET gene rearrangement with robust antitumor activity in response to crizotinib in lung adenocarcinoma［J］.J Thorac Oncol,2018,13(3):29-31.
[22] ZHU Y,WANG W,ZHANG Q,et al.MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma［J］.J Thorac Oncol,2018,13(10):202-204.
[23]PAN Y,ZHANG Y,YE T,et al.Detection of novel NRG1,EGFR and MET fusions in lung adenocarcinomas in the Chinese population［J］.J Thorac Oncol,2019,2019:30-40.
[24]KIM NA,HONG S,KIM KH,et al.New preclinical development of a c-Met inhibitor and its combined anti-tumor effect in c-Met-Amplified NSCLC［J］.Pharmaceutics,2020,12(2):121-122.
[25]TACAR SY,YILMAZ M,OZ B,et al.Crizotinib for c-MET-amplified advanced NSCLC:a single-center experience［J］.［2021-04-13］.https://pubmed.ncbi.nlm.nih.gov/33849345/.
[26]DRILON A,CLARK JW,WEISS J,et al.Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration［J］.Nat Med,2020,26:47-48.
[27]ENGSTROM LD,ARANDA R,LEE M,et al.Glesatinib exhibits antitumor activity in lung cancer models and patients harboring exon 14 mutations and overcomes mutation-mediated resistance to type Ⅰ MET inhibitors in nonclinical models［J］.Clinical Cancer Research,2017,23(21):6661-6672.
[28]CLEMENSON C,CHARGARI C,LIU W,et al.The MET/AXL/FGFR inhibitor S49076 impairs aurora B activity and improves the antitumor efficacy of radiotherapy［J］.Mol Cancer Ther,2017,16:2107-2119.
[29]CUI QB,CAI CHAO Y,GAO HLG,et al.Glesatinib,a c-MET/SMO dual inhibitor,antagonizes P-glycoprotein mediated multidrug resistance in cancer cells［J］.Frontiers in Oncology,2019,9:313-314.
[30]PAZ-ARES,LUIS.Resultsfrom the phase Ⅲ randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage Ⅲb or Ⅳ non-small-cell lung cancer:MET lung（vol 35，pg 412，2017）［J］.Journal of Clinical Oncology,2018,36(8):833-834.
[31]WOLF J,SETO T,HAN JY,et al.Capmatinib in MET ex14-mutated advanced non-small cell lung cancer(NSCLC):efficacy data from the phase Ⅱ GEOMETRY mono-1 study［J］.J Clin Oncol,2019,37:9004-9017.
[32]ROSEN LS,GOLDMAN JW,ALGAZI AP,et al.A first-in-human phase Ⅰ study of a bivalent MET antibody emibetuzumab(LY2875358)as monotherapy and in combination with erlotinib in advanced cancer［J］.Clin Cancer Res,2017,23:1910-1919.
[33]SCAGLIOTTI G,MORO-SIBILOT D,KOLLMEIER J,et al.A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients［J］.J Thorac Oncol,2019,10(19):1556-1581.
[34]TARHINI AA,RAFIQUE I,FLOROS T,et al.Phase 1/2 study of rilotumumab(AMG 102),a hepatocyte growth factor inhibitor,and erlotinib in patients with advanced non-small cell lung cancer［J］.Cancer,2017,123:2936-2944.
[35]ROY S HERBST,PAUL BAAS,DONG WAN KIM,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer(KEYNOTE-010):a randomised controlled trial［J］.The Lancet,2016,387(10027):1540-1550.
[36]BRAHMER JULIE,RECKAMP KAREN L,BAAS PAUL,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,373(2):123-135.
[37]BORGHAEI H,PAZ-ARES L,HORN L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.The New England Journal of Mmedicine,2015,373(17):1627-1639.
[38]RIZVI NAIYER A,HELLMANN MATTHEW D,SNYDER ALEXANDRA,et al.Cancer immunology mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］.Science(New York),2015,348(6230):124-128.
[39]易善永,赵玲,易强,等.肿瘤突变负荷在非小细胞肺癌免疫靶向治疗疗效预测中的应用［J］.中国临床研究,2019,32(4):566-569. YI SY,ZHAO L,YI Q,et al.Application of tumor mutation load in predicting the efficacy of immunotargeting therapy for non-small cell lung cancer［J］.Chinese Clinical Research,2019,32(4):566-569.
[40]SPIGEL DR,SCHROCK AB,FABRIZIO D,et al.Total mutation burden in lung cancer and relationship with response to PD-1/PD-L1 targeted therapies［J］.J Clin Oncol,2016,34(15):9017-9018.
[41]GAINORJF,SHAW AT,SEQUIST LV,et al.EGFR mutations and ALK Rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer:a retrospective analysis［J］.Clinical Cancer Research,2016,22(18):4585-4593.
[42]REUNGWETWATTANA T,LIANG Y,ZHU V,et al.The race to target MET exon 14 skipping alterations in non-small cell lung cancer:The why the how the who the unknown and the inevitable［J］.Lung Cancer,2017,103:27-37.
[43]MARTIN VALENTINA,CHIRIACO CRISTINA,MODICA CHIARA,et al.Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours［J］.British Journal of Cancer,2019,120(5):527-536.

Memo

Memo:
-
Last Update: 2021-12-02